摘要: Gastrointestinal stromal tumor (GIST) is a rare neoplasm that accounts for 5% of all soft tissue sarcomas.1 It the most common mesenchymal gastrointestinal tract. Before advent immunohistologic methods, spindle cell sarcomas tract were considered to be leiomyomas or leiomyosarcomas, with occasional examples neurogenic tumors. GIST defines distinct group tumors originate from intestinal cells Cajal. These act as regulators bowel peristalsis and therefore are also called pacemaker cells. Cajal normally express cKIT (CD 117), which tyrosine kinase growth factor receptor. This immunoreactivity best defining feature GISTs, distinguishing them true smooth muscle (i.e., leiomyosarcomas) arising neural crest derivatives schwannomas neurofibromas); this specific criterion diagnosis GIST. In addition, targeting receptor inhibitor [STI-571, imatinib (gleevec); Novartis, Basel, Switzerland] has been successfully utilized in treating patients
springer.com
elsevier.com
sci-hub.st 参考文章(61)
Helen E. Remotti, Frank Aldenborg, Jeanne M. Meis-Kindblom, Lars Gunnar Kindblom, Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology. ,vol. 152, pp. 1259- 1269 ,(1998)
Katsumi Abe, Hitoshi Terada, Tomohiko Masumoto, Kenzou Suzuki, Takashi Ushimi, Noriko Kamata, Hisao Koga, Ayako Tamura, Yujiro Matsuoka, Yoshiaki Yokoyama, Positive and negative oral contrast agents for combined abdominal and pelvic helical CT: first iodinated agent and second water. Radiation Medicine. ,vol. 18, pp. 213- 216 ,(2000)
Richard Pazdur, Mark Rothmann, Donna Griebel, Ann Staten, Jogarao Gobburu, Atiqur Rahman, Gang Chen, Gabriel Robbie, Gene Williams, Martin Cohen, Ramzi Dagher, Approval Summary Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors Clinical Cancer Research. ,vol. 8, pp. 3034- 3038 ,(2002)
Ihor Pidhorecky, Richard T. Cheney, William G. Kraybill, John F. Gibbs, Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Annals of Surgical Oncology. ,vol. 7, pp. 705- 712 ,(2000) , 10.1007/S10434-000-0705-6
Heikki Joensuu, Christopher Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter Roberts, George Demetri, Management of malignant gastrointestinal stromal tumours. Lancet Oncology. ,vol. 3, pp. 655- 664 ,(2002) , 10.1016/S1470-2045(02)00899-9
Angela D. Levy, Helen E. Remotti, William M. Thompson, Leslie H. Sobin, Markku Miettinen, Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics. ,vol. 23, pp. 283- 304 ,(2003) , 10.1148/RG.232025146
S. Lau, K.F. Tam, C.K. Kam, C.Y. Lui, C.W. Siu, H.S. Lam, K.L. Mak, Imaging of gastrointestinal stromal tumour (GIST). Clinical Radiology. ,vol. 59, pp. 487- 498 ,(2004) , 10.1016/J.CRAD.2003.10.018
Israel Zighelboim, Gwendolyn Henao, Anand Kunda, Carolina Gutierrez, Creighton Edwards, Gastrointestinal stromal tumor presenting as a pelvic mass. Gynecologic Oncology. ,vol. 91, pp. 630- 635 ,(2003) , 10.1016/J.YGYNO.2003.08.025
Markku Miettinen, Martti Virolainen, Maarit-Sarlomo-Rikala, Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas The American Journal of Surgical Pathology. ,vol. 19, pp. 207- 216 ,(1995) , 10.1097/00000478-199502000-00009
Allan T van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, Andrew Webb, Raf Sciot, Martine Van Glabbeke, Sandra Silberman, Ole S Nielsen, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. ,vol. 358, pp. 1421- 1423 ,(2001) , 10.1016/S0140-6736(01)06535-7